Can pemetinib treat cholangiocarcinoma?

Pemetinib, as an innovative targeted therapy drug, has shown impressive efficacy in the treatment of cholangiocarcinoma. The drug is targeted at patients with cholangiocarcinoma (CCA) who carry changes in the fibroblast growth factor receptor (FGFR), specifically those with FGFR2 gene fusions or rearrangements. In the field of cholangiocarcinoma, a highly aggressive malignancy with limited treatment options, the emergence of pemetinib brings new treatment hope and survival opportunities to patients.

In the landmark clinical trial FIGHT-202, pemetinib (another name for pemegatinib) demonstrated significant efficacy in patients with cholangiocarcinoma with FGFR alterations. The trial evaluated the safety and efficacy of pemetinib in patients with locally advanced or metastatic cholangiocarcinoma who had failed prior treatment. Trial results show that pemetinib can effectively control tumor growth and prolong patients' progression-free survival (PFS) and overall survival (OS). These encouraging data provide strong support for the effectiveness of pemetinib in the treatment of cholangiocarcinoma.

However, despite encouraging results from the FIGHT-202 trial, data on the specific patterns and outcomes of pemetinib in cholangiocarcinoma in the real world are still limited. This is mainly because there are certain differences between the conditions and patient groups of clinical trials and those in the real world. Therefore, to better guide clinical practice, we also need to collect more real-world evidence to evaluate the efficacy and safety of pemetinib in different patient groups.

In the real world, pemetinib treatment patterns and outcomes may be affected by a variety of factors, including the patient's specific condition, choice of treatment regimen, drug tolerance and side effects, etc. Therefore, when doctors decide to use pemetinib to treat patients with cholangiocarcinoma, they need to comprehensively consider the patient's specific situation and clinical evidence to formulate a personalized treatment plan.

In summary, pemetinib, a targeted therapy for patients with cholangiocarcinoma with FGFR alterations, demonstrated significant efficacy in the FIGHT-202 trial. Although real-world evidence is still limited, pemetinib undoubtedly provides a new treatment option for patients with cholangiocarcinoma and provides an important reference for future clinical practice and research.

xa0

Reference link: https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae204/7739122?login=false